Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Avalo Therapeutics (AVTX) Short term Debt (2016 - 2025)

Avalo Therapeutics filings provide 8 years of Short term Debt readings, the most recent being $370000.0 for Q2 2025.

On a quarterly basis, Short term Debt changed N/A to $370000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $370000.0, a N/A change, with the full-year FY2024 number at $360000.0, changed N/A from a year prior.
Short term Debt hit $370000.0 in Q2 2025 for Avalo Therapeutics, up from $360000.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $370000.0 in Q2 2025 to a low of $360000.0 in Q4 2024.